Sera Prognostics Appoints Jeff Elliott to Board as Key Transitions Unfold

Sera Prognostics Welcomes New Board Member Amid Leadership Changes

Sera Prognostics Inc., known as The Pregnancy Company®, has recently made an important announcement regarding its leadership. Effective March 20, 2025, Jeff Elliott will join the company’s Board of Directors, filling the vital role at a time when the organization is evolving to enhance maternal and neonatal health through its innovative products. This decision reflects Sera's commitment to ensuring it has the right expertise to navigate the unique challenges and opportunities in the healthcare diagnostics field, specifically in pregnancy health.

In his new position, Elliott brings a wealth of experience that is crucial for the strategic direction of Sera Prognostics. His background includes notable positions, such as Chief Financial Officer at Exact Sciences, where he led significant initiatives and successfully scaled the company during his tenure from 2016 until May 2024. Zhenya Lindgardt, the President and CEO of Sera Prognostics, expressed enthusiasm about Elliott joining the board, emphasizing his ability to utilize his expertise in corporate strategy and operations to bolster Sera’s mission.

Meanwhile, the company is in the process of refreshing its board. Ryan Trimble, who has dedicated 14 years to serving Sera, has announced his retirement, effective June 30, 2025. His leadership has been instrumental in guiding the company to its current state as a leader in pregnancy health. Marcus Wilson, another long-serving director, has also decided not to seek reelection at the upcoming 2025 Annual Meeting of Stockholders. Both departures coincide with Sera’s ongoing efforts to rejuvenate its board's composition and expertise.

The Value of Experience

Elliott’s proven track record in scaling companies in the healthcare sector can play a pivotal role as Sera turns its focus towards leveraging its recent PRIME study results. This study is crucial for the company’s flagship PreTRM® test, which aims at predicting the risk of preterm births, a significant concern in maternal healthcare. Under Elliott’s guidance, Sera aims to enhance its market strategy and improve clinical outcomes for mothers and their babies. The PreTRM test stands out as an innovative tool that detects elevated risk for premature delivery, enabling timely intervention and improved care.

Reflecting on his tenure, Trimble remarked on the progress Sera has made since he joined, indicating satisfaction in leaving the company in capable hands as it moves into the next chapter of its growth. Both Trimble and Wilson shared their gratitude for the opportunity to contribute to the company’s mission, highlighting the impactful work being done in the realm of pregnancy health diagnostics.

Collaboration for Maternal and Neonatal Health

Sera Prognostics is focused on providing actionable insights through diagnostic tests that inform physicians about the risks associated with pregnancy. The company is renowned for its commitment to precision medicine, striving to deliver tailored care to women facing high risks during pregnancy. With the appointment of Elliott and the strategic shifts underway, Sera is well-positioned to expand its influence and improve care for mothers and newborns.

As the organization prepares for these transitions, it stands firm on its mission: to empower healthcare providers with crucial information that can lead to better health outcomes. The continued innovation in the PreTRM test reflects not just the company's dedication to maternal and neonatal health, but also its commitment to reducing healthcare costs associated with premature births.

In conclusion, Sera Prognostics' strategic maneuvers in leadership highlight a proactive approach to navigating the healthcare landscape successfully. With Jeff Elliott on board, alongside the contributions of invaluable departing members Trimble and Wilson, the company enters a promising phase that may redefine standards in pregnancy health diagnostics.